Cited by 283Lung Cancer Treatments and MutationsCell death mechanisms and regulationHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors

Open access

Faber, Anthony C., Corcoran, Ryan B., Ebi, Hiromichi, Sequist, Lecia V., Waltman, Belinda A., Chung, Euiheon, Incio, Joao, Digumarthy, Subba R., Pollack, Sarah F., Song, Youngchul, Muzikansky, Alona, Lifshits, Eugene, Roberge, Sylvie, Coffman, Erik J., Benes, Cyril H., Gómez, Henry L., Baselga, José, Arteaga, Carlos L., Rivera, Miguel N., Dias-Santagata, Dora, Jain, Rakesh K., Engelman, Jeffrey A.·2011·Cancer Discovery

DOI 10.1158/2159-8290.cd-11-0106PMC PMC3229203

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Cancers with specific genetic mutations are susceptible to selective kinase inhibitors. However, there is a wide spectrum of benefit among cancers harboring the same sensitizing genetic mutations. Herein, we measured apoptotic rates among cell lines sharing the same driver oncogene following treatment with the corresponding kinase inhibitor. There was a wide range of kinase inhibitor-induced apoptosis despite comparable inhibition of the target and associated downstream signaling pathways. Surprisingly, pretreatment RNA levels of the BH3-only pro-apoptotic BIM strongly predicted the capacity of EGFR, HER2, and PI3K inhibitors to induce apoptosis in EGFR-mutant, HER2-amplified, and PIK3CA-mutant cancers, respectively, but BIM levels did not predict responsiveness to standard chemotherapies. Furthermore, BIM RNA levels in EGFR-mutant lung cancer specimens predicted response and duration of clinical benefit from EGFR inhibitors. These findings suggest assessment of BIM levels in treatment-naïve tumor biopsies may indicate the degree of benefit from single-agent kinase inhibitors in multiple oncogene-addiction paradigms. Significance: In several oncogene-addiction paradigms, assessment of BIM RNA levels identifies those cancers that fail to have substantial apoptotic responses to kinase inhibitors. BIM RNA levels may be assessed in diagnostic cancer specimens to predict which patients will receive less benefit from single-agent kinase inhibitors. Cancer Discovery: 1(4); 352–65. ©2011 AACR. Read the Commentary on this article by Yoshida and Haura, p. 289 This article is highlighted in the In This Issue feature, p. 275

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-11-0106

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Self-citation
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M. A., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,873
Self-citation
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members
Certo, M. V., Moore, V. D. G., Nishino, M., Wei, G., Korsmeyer, S. J., Armstrong, S. A., & Letai, A. G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.027 · Cited by 1,278
Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes
Xiao, C., Srinivasan, L., Calado, D. P., Patterson, H. C., Zhang, B., Wang, J., Henderson, J., Kutok, J. L., & Rajewsky, K. (2008) · Nature Immunology · doi:10.1038/ni1575 · Cited by 1,248
Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak
Willis, S. N., Fletcher, J. I., Kaufmann, T., van Delft, M. F., Chen, L., Czabotar, P. E., Ierino, H., Lee, E. F., Fairlie, W. D., Bouillet, P., et al. (2007) · Science · doi:10.1126/science.1133289 · Cited by 1,146
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059
Self-citation

Show all 50 references

Sorted by citations

Items 101–200 of 282

The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
Laface, C., Maselli, F. M., Santoro, A. N., Iaia, M. L., Ambrogio, F., Laterza, M., Guarini, C., Santis, P. D., Perrone, M., & Fedele, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061604 · Cited by 63
CDK Inhibitors Upregulate BH3-Only Proteins to Sensitize Human Myeloma Cells to BH3 Mimetic Therapies
Chen, S., Dai, Y., Pei, X.-Y., Myers, J. L., Wang, L., Kramer, L. B., Garnett, M., Schwartz, D. M., Su, F., Simmons, G. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1118 · Cited by 54
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation
Anderson, G. R., Wardell, S. E., Cakir, M., Crawford, L., Leeds, J. C., Nussbaum, D. P., Shankar, P. S., Soderquist, R. S., Stein, E. M., Tingley, J. P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aae0348 · Cited by 53
Mechanisms of intrinsic and acquired resistance to kinase‐targeted therapies
Bagrodia, S., Smeal, T., & Abraham, R. T. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12007 · Cited by 56
Collagen type I induces EGFR ‐ TKI resistance in EGFR ‐mutated cancer cells by mTOR activation through Akt‐independent pathway
Yamazaki, S., Higuchi, Y., Ishibashi, M., Hashimoto, H., Yasunaga, M., Matsumura, Y., Tsuchihara, K., Tsuboi, M., Goto, K., Ochiai, A., et al. (2018) · Cancer Science · doi:10.1111/cas.13624 · Cited by 52
Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer
Zeng, Y., Yu, D., Tian, W., & Wu, F. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000805 · Cited by 52
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2+ breast cancer cells by inducing Bim
Park, S. H., Ito, K., Olcott, W., Katsyv, I., Halstead-Nussloch, G., & Irie, H. Y. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0594-z · Cited by 49
Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR -mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)
Bertino, E. M., Gentzler, R. D., Clifford, S. E., Kolesar, J., Muzikansky, A., Haura, E. B., Piotrowska, Z., Camidge, D. R., Stinchcombe, T. E., Hann, C. L., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4084 · Cited by 48
Self-citation
Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK / ROS1 fusion‐positive non–small cell lung cancer
Zhang, L., Jiang, T., Li, X., Wang, Y., Zhao, C., Zhao, S., Xi, L., Zhang, S., Liu, X., Jia, Y., et al. (2017) · Cancer · doi:10.1002/cncr.30677 · Cited by 48
Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
Karlsen, E., Kahler, S. L., Tefay, J., Joseph, S. R., & Simpson, F. (2021) · Cells · doi:10.3390/cells10051206 · Cited by 52
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
Lee, J. Y., Ku, B. M., Lim, S. H., Lee, M., Kim, H., Kim, M., Kim, S., Jung, H. A., Sun, J., Ahn, J. S., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000535 · Cited by 48
Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2
Karakashev, S. V., & Reginato, M. J. (2015) · Oncotarget · doi:10.18632/oncotarget.2806 · Cited by 46
PIK3CA and TP53 Gene Mutations in Human Breast Cancer Tumors Frequently Detected by Ion Torrent DNA Sequencing
Bai, X., Zhang, E., Ye, H., Nandakumar, V., Wang, Z., Chen, L., Tang, C., Li, J., Li, H., Zhang, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099306 · Cited by 46
Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small-Cell Lung Cancer
Lee, J., Lin, Y., Hsu, W., Chen, H., Chang, Y., Yu, C., Shih, J., Lin, C., Chen, K., Ho, C., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000238 · Cited by 44
Farnesoid X receptor, a novel proto-oncogene in non-small cell lung cancer, promotes tumor growth via directly transactivating CCND1
You, W., Chen, B., Liu, X., Xue, S., Qin, H., & Jiang, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-00698-4 · Cited by 44
Non‐small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
Huang, J., Wang, Y., Zhai, Y., & Wang, J. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12637 · Cited by 44
c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors
Liu, H., Ai, J., Shen, A., Chen, Y., Wang, X., Xia, P., Chen, H., Shen, Y., Huang, M., Ding, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2448 · Cited by 43
The RAS‐related GTPase RHOB confers resistance to EGFR‐tyrosine kinase inhibitors in non‐small‐cell lung cancer via an AKT‐dependent mechanism
Calvayrac, O., Mazières, J., Figarol, S., Marty‐Detraves, C., Raymond‐Letron, I., Bousquet, E., Farella, M., Clermont, E., Milia, J., Rouquette, I., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606646 · Cited by 41
Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability
Wu, D.-W., Chen, C.-Y., Chu, C.-L., & Lee, H. (2015) · Oncogene · doi:10.1038/onc.2015.120 · Cited by 39
Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions
Kuan, F., Li, S., Wang, C., Lin, M., Tsai, Y., & Yang, C. (2016) · Oncotarget · doi:10.18632/oncotarget.13815 · Cited by 40
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
Ricciuti, B., Baglivo, S., Paglialunga, L., Giglio, A. D., Bellezza, G., Chiari, R., Crinò, L., & Metro, G. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017702820 · Cited by 39
Epithelial-to-mesenchymal transition and drug resistance: transitioning away from death
Song, K.-A., & Faber, A. C. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.06.11 · Cited by 38
Self-citation
Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges
Zhang, Z., Hou, L., Liu, D., Luan, S., Huang, M., & Zhao, L. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.02.010 · Cited by 42
Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies
Asić, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.004 · Cited by 38
The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity
Heisey, D. A. R., Lochmann, T. L., Floros, K. V., Coon, C. M., Powell, K. M., Jacob, S., Calbert, M. L., Ghotra, M. S., Stein, G. T., Maves, Y. K., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0277 · Cited by 35
Self-citation
Cell-Intrinsic Mechanisms of Drug Tolerance to Systemic Therapies in Cancer
Léonce, C., Saintigny, P., & Ortiz‐Cuaran, S. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0038 · Cited by 41
Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation
Ono, A., Kenmotsu, H., Watanabe, M., Serizawa, M., Mori, K. P., Imai, H., Taira, T., Naito, T., Murakami, H., Nakajima, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu251 · Cited by 38
Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer
Izar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 38
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
Brazel, D., Kroening, G., & Nagasaka, M. (2022) · BioDrugs · doi:10.1007/s40259-022-00556-4 · Cited by 37
Role of TM4SF1 in regulating breast cancer cell migration and apoptosis through PI3K/AKT/mTOR pathway.
Sun, Y., Xu, Y., Xu, J., Lü, D., & Wang, J. (2015) · PubMed Central · Cited by 37
Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer
Takeuchi, S., Hase, T., Shimizu, S., Ando, M., Hata, A., Murakami, H., Kawakami, T., Nagase, K., Yoshimura, K., Fujiwara, T., et al. (2019) · Cancer Science · doi:10.1111/cas.14260 · Cited by 37
MiR-24-BIM-Smac/DIABLO axis controls the sensitivity to doxorubicin treatment in osteosarcoma
Sun, Y., He, N., Dong, Y., & Jiang, C. (2016) · Scientific Reports · doi:10.1038/srep34238 · Cited by 36
Identification of predictive factors of response to the BH3‐mimetic molecule ABT‐737: An ex vivo experiment in human serous ovarian carcinoma
Lheureux, S., N’Diaye, M., Blanc‐Fournier, C., Dugué, A. E., Clarisse, B., Dutoit, S., Giffard, F., Abeilard, E., Briand, M., Labiche, A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29104 · Cited by 43
A common functional consequence of tumor-derived mutations within c-MYC
Chakraborty, A. A., Scuoppo, C., Dey, S., Thomas, L. R., Lorey, S. L., Lowe, S. W., & Tansey, W. P. (2014) · Oncogene · doi:10.1038/onc.2014.186 · Cited by 35
The Sensitivity of Diffuse Large B-Cell Lymphoma Cell Lines to Histone Deacetylase Inhibitor-Induced Apoptosis Is Modulated by BCL-2 Family Protein Activity
Thompson, R. C., Vardinogiannis, I., & Gilmore, T. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062822 · Cited by 34
Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216
Walls, M., Baxi, S. M., Mehta, P. P., Liu, K. K. ‐., Zhu, J., Estrella, H., Li, C., Zientek, M. A., Zong, Q., Smeal, T., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1663 · Cited by 34
Retracted
Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha–Positive, PIK3CA -Mutant Breast Cancer
Yang, W., Hosford, S. R., Dillon, L. M., Shee, K., Liu, S. C., Bean, J. R., Salphati, L., Pang, J., Zhang, X., Nannini, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2276 · Cited by 34
Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench
Suda, K., Bunn, P. A., Rivard, C. J., Mitsudomi, T., & Hirsch, F. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.003 · Cited by 33
PRKCQ inhibition enhances chemosensitivity of triple-negative breast cancer by regulating Bim
Byerly, J. H., Port, E. R., & Irie, H. Y. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01302-w · Cited by 33
Autophagy promotes escape from phosphatidylinositol 3‐kinase inhibition in estrogen receptor‐positive breast cancer
Yang, W., Hosford, S. R., Traphagen, N. A., Shee, K., Demidenko, E., Liu, S., & Miller, T. W. (2017) · The FASEB Journal · doi:10.1096/fj.201700477r · Cited by 33
Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation
Zhao, B.-X., Wang, J., Song, B., WEI, H., Lv, W., TIAN, L.-M., Li, M., & Lv, S. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.3058 · Cited by 32
Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids
Vernon, M., Lambert, B., Meryet‐Figuière, M., Brotin, É., Weiswald, L., Paysant, H., Vigneron, N., Wambecke, A., Abeilard, E., Giffard, F., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0510 · Cited by 36
Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
Nishihara, S., Yamaoka, T., Ishikawa, F., Higuchi, K., Hasebe, Y., Manabe, R., Kishino, Y., Kusumoto, S., Andō, K., Kuroda, Y., et al. (2022) · Genes · doi:10.3390/genes13122183 · Cited by 34
Sensitizing non-small cell lung cancer to BCL-xL-targeted apoptosis
Shen, Q., Li, J., Mai, J., Zhang, Z., Fisher, A., Wu, X., Li, Z., Ramirez, M., Chen, S., & Shen, H. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1040-9 · Cited by 30
Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer
Shimizu, T., Nishio, K., Sakai, K., Okamoto, I., Okamoto, K., Takeda, M., Morishita, M., & Nakagawa, K. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04112-1 · Cited by 30
ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins
Alcon, C., Zañudo, J. G. T., Albert, R., Wagle, N., Scaltriti, M., Letai, A. G., Samitier, J., & Montero, J. (2021) · Cells · doi:10.3390/cells10071659 · Cited by 32
Targeting the Regulatory Machinery of BIM for Cancer Therapy
Harada, H., & Grant, S. (2012) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v22.i2.40 · Cited by 30
Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy
Floros, K. V., Lochmann, T. L., Hu, B., Monterrubio, C., Hughes, M. T., Wells, J. D., Morales, C. B., Ghotra, M. S., Costa, C., Souers, A. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717820115 · Cited by 30
Self-citation
The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy
Ying, H.-Q., Chen, J., He, B.-S., Pan, Y.-Q., Wang, F., Deng, Q.-W., Sun, H.-L., Liu, X., & Wang, S.-K. (2015) · Scientific Reports · doi:10.1038/srep11348 · Cited by 29
BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations
Cardona, A. F., CLICaP, O. B. O. T., Rojas, L., Wills, B., Arrieta, O., Carranza, H., Vargas, C., Otero, J., Corrales-Rodriguez, L., Martín, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12112 · Cited by 29
Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer
Delahaye, C., Figarol, S., Pradines, A., Favre, G., Mazières, J., & Calvayrac, O. (2022) · Cancers · doi:10.3390/cancers14112613 · Cited by 32
Nicotinic neuromodulation in auditory cortex requires MAPK activation in thalamocortical and intracortical circuits
Intskirveli, I., & Metherate, R. (2012) · Journal of Neurophysiology · doi:10.1152/jn.01129.2011 · Cited by 31
Lemur tyrosine kinase 2 (LMTK2) is a determinant of cell sensitivity to apoptosis by regulating the levels of the BCL2 family members
Conti, A., Majorini, M. T., Fontanella, E., Bardelli, A., Giacca, M., Delia, D., Mano, M., & Lecis, D. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.12.025 · Cited by 29
Image-guided strategies to improve drug delivery to tumors beyond using the enhanced permeability and retention (EPR) effect
Rama, E., May, J., Rix, A., Lammers, T., & Kiessling, F. M. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152346 · Cited by 28
Advances in Molecular Biology of Lung Disease
Rooney, C., & Sethi, T. (2015) · CHEST Journal · doi:10.1378/chest.14-2663 · Cited by 29
Targeting drug‐tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells
Song, X.-H., Yang, L., Zheng, X., Zhu, Q., Liao, X.-L., Liu, K., Zhang, W., Peng, Q., Zhu, Y., Zhao, L.-Y., et al. (2023) · MedComm · doi:10.1002/mco2.342 · Cited by 28
Systems biology approaches to develop innovative strategies for lung cancer therapy
Viktorsson, K., Lewensohn, R., & Zhivotovsky, B. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.28 · Cited by 27
TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing.
Zheng, H., Wang, Y., Tang, C., Jones, L. E., Ye, H., Zhang, G., Cao, W., Li, J., Liu, L., Liu, Z., et al. (2016) · PubMed · Cited by 26
BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review
Li, X., Wang, S., Li, B., Wang, Z., Shang, S., Shao, Y. W., Sun, X., & Wang, L. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0573-2 · Cited by 28
The major isoforms of Bim contribute to distinct biological activities that govern the processes of autophagy and apoptosis in interleukin-7 dependent lymphocytes
Ruppert, S. M., Li, W., Zhang, G., Carlson, A. L., Limaye, A., Durum, S. K., & Khaled, A. R. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.06.017 · Cited by 26
A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non–Small Cell Lung Cancer
Owonikoko, T. K., Ramalingam, S. S., Miller, D., Force, S. D., Sica, G., Sheldon, J. M., Chen, Z., Rogatko, A., Tighiouart, M., Harvey, R. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1998 · Cited by 28
Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, T790M, and Clinical Trials
O'Kane, G. M., Barnes, T. A., & Leighl, N. B. (2018) · Current Oncology · doi:10.3747/co.25.3796 · Cited by 25
The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC
Li, S., Zhu, S., Wei, H., Zhu, P., Jiao, Y., Yi, M., Gong, J., Zheng, K., & Zhang, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113959 · Cited by 26
Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR‑TKI
Cheong, H. T., Xu, F., Choy, C. T., Hui, C. W. C., Mok, T. S. K., & Wong, C. H. (2017) · Oncology Letters · doi:10.3892/ol.2017.7377 · Cited by 24
Inhibition of MEK1/2 forestalls the onset of acquired resistance to entrectinib in multiple models of NTRK1-driven cancer
Vaishnavi, A., Scherzer, M. T., Kinsey, C. G., Parkman, G. L., Truong, A., Ghazi, P., Schuman, S., Battistone, B., Garrido-Laguna, I., & McMahon, M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107994 · Cited by 23
IRS1 phosphorylation underlies the non-stochastic probability of cancer cells to persist during EGFR inhibition therapy
Berger, A. J., Gigi, E., Kupershmidt, L., Meir, Z., Gavert, N. S., Zwang, Y., Pri-Or, A., Gilad, S., Harush, U., Haviv, I., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00261-1 · Cited by 22
That which does not kill me makes me stronger; combining ERK 1/2 pathway inhibitors and BH 3 mimetics to kill tumour cells and prevent acquired resistance
Sale, M. J., & Cook, S. J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12220 · Cited by 23
Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome
Remón, J., Morán, T., Reguart, N., Majem, M., Carcereny, E., & LIANES, P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.03.006 · Cited by 22
Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas
Wu, Z., Bai, F., Fan, L., Pang, W., Han, R., Wang, J., Liu, Y., Xia, Y., Duan, H., & Xing, L. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.08.014 · Cited by 21
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer
Sarosiek, K. A., & Wood, K. C. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.10.004 · Cited by 23
Therapeutic management of ALK+nonsmall cell lung cancer patients
Duchemann, B., Friboulet, L., & Besse, B. (2015) · European Respiratory Journal · doi:10.1183/09031936.00236414 · Cited by 22
Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
Becker, K. D. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.560 · Cited by 19
Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy
Li, X., Zhang, D., Li, B., Zou, B., Wang, S., Fan, B., Li, W., Yu, J., & Wang, L. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.12.002 · Cited by 20
Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
Floros, K. V., Jacob, S., Kurupi, R., Fairchild, C. K., Hu, B., Puchalapalli, M., Koblinski, J. E., Dozmorov, M. G., Boikos, S. A., Scaltriti, M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03457-6 · Cited by 20
Self-citation
BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations
Huang, W. F., Liu, A. H., Zhao, H. J., Dong, H., Liu, L. Y., & Cai, S. X. (2015) · Medicine · doi:10.1097/md.0000000000001263 · Cited by 19
t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib
Christenson, J. L., Denny, E. C., & Kane, S. E. (2015) · Oncotarget · doi:10.18632/oncotarget.5311 · Cited by 18
A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib
Nieves, A. S., Lindzen, M., Giri, S., Gupta, N., Chatterjee, R., Selvadurai, B.-R., Daele, M. V., Love, D., Haga, Y., Romaniello, D., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101703 · Cited by 18
ARID3B Induces Tumor Necrosis Factor Alpha Mediated Apoptosis While a Novel ARID3B Splice Form Does Not Induce Cell Death
Joseph, S. J., Deneke, V. E., & Dahl, K. D. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042159 · Cited by 18
Dexmedetomidine alleviates cardiomyocyte apoptosis and cardiac dysfunction may be associated with inhibition of RhoA/ROCK pathway in mice with myocardial infarction
Sun, T., Gong, Q., Wu, Y., Shen, Z., Zhang, Y., Ge, S., & Duan, J. (2021) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-021-02082-6 · Cited by 18
A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer
Soh, S. X., Siddiqui, F. J., Allen, J. C., Kim, G. W., Lee, J. C., Yatabe, Y., Soda, M., Mano, H., Soo, R. A., Chin, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17102 · Cited by 17
Self-citation
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab
Marrocco, I., Giri, S., Nieves, A. S., Gupta, N., Rudnitsky, A., Haga, Y., Romaniello, D., Sekar, A., Zerbib, M., Oren, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101142 · Cited by 18
Harnessing p53 for targeted cancer therapy: new advances and future directions
Andrysík, Z., & Espinosa, J. M. (2025) · Transcription · doi:10.1080/21541264.2025.2452711 · Cited by 19
Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: Sensitivity and resistance
Takeuchi, S., & Yano, S. (2014) · Respiratory Investigation · doi:10.1016/j.resinv.2014.10.002 · Cited by 17
Bcl-XL, but not Bcl-2, can protect human B-lymphoma cell lines from parthenolide-induced apoptosis
Yeo, A. T., Porco, J. A. J., & Gilmore, T. D. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.11.035 · Cited by 17
Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib
Yuan, J., Li, B., Zhang, N., Zhu, H., Zhou, L., Zhang, L., & Yang, M. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.02.007 · Cited by 17
Strategies to Overcome Acquired Resistances Conferred by Mutations in the Kinase Domain of Egfr
Lim, S. M., Jeong, Y., & Hong, S. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0019 · Cited by 16
Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes
Roosan, M. R., MacNeil, S. M., Jenkins, D. F., Shrestha, G., Wyatt, S. R., McQuerry, J. A., Piccolo, S., Heiser, L. M., Gray, J. W., Johnson, W. E., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0429-x · Cited by 16
BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia
Li, Y., Deutzmann, A., Choi, P. S., Fan, A. C., & Felsher, D. W. (2016) · Oncotarget · doi:10.18632/oncotarget.8731 · Cited by 16
hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells
Trono, P., Modugno, F. D., Circo, R., Spada, S., Benedetto, A. D., Melchionna, R., Palermo, B., Matteoni, S., Soddu, S., Mottolese, M., et al. (2015) · Oncogene · doi:10.1038/onc.2015.143 · Cited by 16
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer
Bean, J. R., Hosford, S. R., Symonds, L. K., Owens, P., Dillon, L. M., Yang, W., Shee, K., Schwartz, G. N., Marotti, J. D., Muller, K. E., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3201-6 · Cited by 15
BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer
Rose, M. M., Espinoza, V. L., Hoff, K. J., Pike, L. A., Sharma, V., Hofmann, M.-C. C., Tan, A. C., Pozdeyev, N. V., & Schweppe, R. E. (2023) · Cancers · doi:10.3390/cancers15020378 · Cited by 15
Valproic acid, an inhibitor of class I histone deacetylases, reverses acquired Erlotinib-resistance of lung adenocarcinoma cells: a Connectivity Mapping analysis and an experimental study.
Zhuo, W., Zhang, L. N., Zhu, Y. Z., Xie, Q., Zhu, B., & Chen, Z. (2015) · Europe PMC (PubMed Central) · Cited by 14
Concomitant genetic alterations having greater impact on the clinical benefit of EGFR‐TKIs in EGFR‐mutant advanced NSCLC than BIM deletion polymorphism
Liu, S. M., Zhou, J., Li, W., Sun, H., Zhang, Y., Yan, H., Chen, Z., Chen, C., Ye, J., Yang, J., et al. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.12 · Cited by 14
Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors
Tiedt, R., King, F. J., Stamm, C., Niederst, M. J., Delach, S. M., Zumstein-Mecker, S., Meltzer, J., Mulford, I. J., Labrot, E., Engstler, B. S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112297 · Cited by 13
Self-citation
Lack of Association between the BIM Deletion Polymorphism and the Risk of Lung Cancer with and without EGFR Mutations
Ebi, H., Oze, I., Nakagawa, T., Ito, H. M., Hosono, S., Matsuda, F., Takahashi, M., Takeuchi, S., Sakao, Y., Hida, T., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000371 · Cited by 13
Self-citation
The relationship between BIM deletion polymorphism and clinical significance of epidermal growth factor receptor-mutated non-small cell lung cancer patients with epidermal growth factor receptor-tyrosine kinase inhibitor therapy: a meta-analysis.
Zou, Q., Zhan, P., Lv, T., & Song, Y. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.12.09 · Cited by 13
Self-citation
EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism
Liu, S., He, Y., Jiang, T., Ren, S., Zhou, F., Zhao, C., Li, X., Zhang, J., Su, C., Chen, X., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.04.004 · Cited by 13
Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C -mutant Colorectal Cancer
Khawaja, H., Briggs, R., Latimer, C. H., Rassel, M., Griffin, D., Hanson, L., Bardelli, A., Di Nicolantonio, F., McDade, S. S., Scott, C. J., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0301 · Cited by 12
“Previous in vitro and clinical studies have shown positive correlations between BIM expression and response to anti-EGFR and BRAF drugs in EGFR and BRAF addicted tumors (40, 41).”
Background
The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer
Moonmuang, S., Tantraworasin, A., Orrapin, S., Udomruk, S., Chewaskulyong, B., Pruksakorn, D., & Chaiyawat, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054827 · Cited by 12
Bim is an independent prognostic marker in intrahepatic cholangiocarcinoma
Zhang, H., Jenkins, S. M., Lee, C.-T., Harrington, S. M., Liu, Z., Dong, H., & Zhang, L. (2018) · Human Pathology · doi:10.1016/j.humpath.2018.04.009 · Cited by 12

Authors: Faber, A. C., Corcoran, R. B., Ebi, H., Sequist, L. V., Waltman, B. A., Chung, E., Incio, J., Digumarthy, S. R., Pollack, S. F., Song, Y., Muzikansky, A., Lifshits, E., Roberge, S., Coffman, E. J., Benes, C. H., Gómez, H. L., Baselga, J., Arteaga, C. L., Rivera, M. N., Dias-Santagata, D., Jain, R. K., & Engelman, J. A.
Affiliations: Harvard University (US)
Authors' Affiliations: 1Pathology and 2Radiology, Massachusetts General Hospital, Boston; 3Massachusetts General Hospital Cancer Center, Boston; 4Department of Medicine, Harvard Medical School, Boston; 5Radiation Oncology, Steele Lab for Tumor Biology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts; 6Department of Medicine, 7Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; 8Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
Corresponding author: Engelman, Jeffrey A.
ORCID: Faber, Anthony C.
Corcoran, Ryan B.
Ebi, Hiromichi
Sequist, Lecia V.
Chung, Euiheon
Digumarthy, Subba R.
Song, Youngchul
Muzikansky, Alona
Roberge, Sylvie
Benes, Cyril H.
Gómez, Henry L.
Arteaga, Carlos L.
Rivera, Miguel N.
Dias-Santagata, Dora
Engelman, Jeffrey A.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2011-09-01
Volume: 1
Issue: 4
Pages: 352-365
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-11-0106
PMC: PMC3229203
OpenAlex: W2117986690
Cited by: 283
References: 50
Citations by year: 2026: 9 · 2025: 6 · 2024: 4 · 2023: 11 · 2022: 13 · 2021: 15 · 2020: 15 · 2019: 8 · 2018: 27 · 2017: 26 · 2016: 27 · 2015: 31 · 2014: 34 · 2013: 33 · 2012: 22
FWCI: 24.81
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Vanderbilt University
Vanderbilt-Ingram Cancer Center
National Cancer Institute (P50CA127003, R01CA080195, R01CA140594, P50CA090578, P01CA080124, P20CA090578, R01CA135257, K08CA120060, P50CA098131, R01CA137008)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: building information modeling, BH3-only proteins, kinase inhibitors, predictive biomarkers, apoptosis, EGFR inhibitors, HER2 inhibitors, PI3K inhibitors, oncogene addiction, EGFR-mutant lung cancer, PIK3CA mutation, treatment-naive tumors, drug response prediction
MeSH terms: Bcl-2-Like Protein 11, Phosphoinositide-3 Kinase Inhibitors, Animals, Female, Humans, Lung Neoplasms, Membrane Proteins, Mice, Nude, Oncogenes, Proto-Oncogene Proteins, Retrospective Studies, Cohort Studies, Signal Transduction, Apoptosis, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Phosphatidylinositol 3-Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Apoptosis Regulatory Proteins, BH3 Interacting Domain Death Agonist Protein, Mice, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks